Market Research Report
Hepatitis Test Solution/Diagnosis Market by Disease Type (Hepatitis B, HCV, HAV, HDV), Technology (ELISA, RDT, PCR, Transcription Mediated Amplification), End User (Hospitals, Diagnostic Laboratories, Blood Banks, Nursing Homes), Global Forecast to 2023
|Published by||MarketsandMarkets||Product code||718223|
|Published||Content info||113 Pages
Delivery time: 1-2 business days
|Hepatitis Test Solution/Diagnosis Market by Disease Type (Hepatitis B, HCV, HAV, HDV), Technology (ELISA, RDT, PCR, Transcription Mediated Amplification), End User (Hospitals, Diagnostic Laboratories, Blood Banks, Nursing Homes), Global Forecast to 2023|
|Published: October 2, 2018||Content info: 113 Pages||
The hepatitis test solution/diagnosis market is expected to reach USD 3.37 billion by 2023 from USD 2.66 billion in 2018, growing at a CAGR of 4.9% during the forecast period. The growth of this market can be attributed to the high burden of hepatitis worldwide, benefits offered by point of care instruments & kits, and initiatives taken by government and non-government organizations. However, lack of mandate for NAT in developing countries and the high cost of NAT test are expected to restrain the growth of this market during the forecast period.
By technology, the hepatitis test solution/diagnosis market is segmented into ELISA, rapid diagnostics test, PCR, INAAT, and other technologies. RDT is projected to grow at the highest CAGR during the forecast period. This growth is mainly attributed to the low cost of this test type, its high analytical sensitivity, and its ability to detect all known 11 subtypes of HBsAg.
The market is classified on the basis of disease type into hepatitis B, hepatitis C, and other hepatitis disease. In terms of value, the hepatitis B segment is expected to account for the largest share of the market in 2018. This can primarily be attributed to the rising prevalence of hepatitis B, availability of a large number of hepatitis B diagnostic tests, and the increasing adoption of NAT test in HBV blood screening.
North America is expected to account for the largest share of the global hepatitis test solution/diagnosis market in 2018. This is primarily attributed to factors such as rising adoption of advanced technologies, developed healthcare systems in the US and Canada, and the presence of a large number of leading national clinical laboratories. Followed by North America, Europe is expected to account for the second-largest share of the global hepatitis test solution/diagnosis market in 2018.
Abbott Laboratories (US), Roche (Switzerland), Bio-Rad (US), Siemens (Germany), DiaSorin (Italy), QIAGEN (Netherlands), Danaher (US), bioMerieux (France), and Grifols (Spain) are some of the key players operating in this market.
The hepatitis test solution/diagnosis market studied in this report is segmented by disease type, technology, end user, and region. The study tracks and analyzes competitive developments such as product launches; expansions; agreements, partnerships, and collaborations; and acquisitions. It also profiles the key players and their core competencies within the hepatitis test solution/diagnosis market.
The report provides insights on the following pointers:
*Details on Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.